Matuzumab in doubt after trial failure

There's trouble at Merck Serono's program for Matuzumab, which is in development for colorectal cancer. Merck KGaA says it is "reconsidering" further development of the therapy after the drug failed to hit its endpoint in a Phase II trial. Merck Serono and Takeda have a joint development pact for the drug, which failed to meet their expectations. More work, though, is being planned for other tumor types.

- check out the release

Related Articles:
Takeda expands R&D budget, may look for buyout. Report
Merck KGaA buying control of Serono. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.